This site is intended for US health care professionals.
01. Foundational / Icons / 32x32px/Menu @1x Open Menu 01. Foundational / Icons / 32x32px/Close @1x Close Menu
Actor Portrayal

Did you know M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is also for adults?1

Choose M-M-R®II for your adult patients

PRIORIX IMMUNE RESPONSE: STUDY 4: Immune responses to PRIORIX as a second dose compared with M-M-R®II in participants 7 years of age and older (ATP population)2,3

Study results:

PRIORIXa was non-inferior compared with M-M-R®II in terms of SRR and antibody GMC to measles (SRR M-M-R®II 99% vs PRIORIX 99%; GMC (mIU/mL) M-M-R®II 1,783 vs PRIORIX 1,754; GMC Ratio PRIORIX/M-M-R®II, 0.98; 95% CI, 0.89, 1.09), mumps (SRR M-M-R®II 100% vs PRIORIX 98%; GMC (ELU/mL) M-M-R®II 110 vs PRIORIX 114; GMC Ratio PRIORIX/M-M-R®II, 1.04; 95% CI, 0.94, 1.15), and rubella (SRR M-M-R®II 100% vs PRIORIX 100%; GMC (IU/mL) M-M-R®II 74 vs PRIORIX 76; GMC Ratio PRIORIX/M-M-R®II, 1.03; 95% CI, 0.94, 1.12).2,3

Study design:
Randomized, observer-blind, controlled study, conducted in the US, Slovakia, and Estonia, 860 participants 7 years of age and older (median age, 26 years; 7-59 years) received PRIORIX (n=426) or M-M-R®II (n=434) as a second dose following previous administration of a combined MMR-containing vaccine. Antibody responses to measles, mumps, and rubella were measured 42 days following the second dose of either vaccine.2,3,b

aPRIORIX (Measles, Mumps, and Rubella Vaccine, Live) is a registered trademark of GSK.
bSource: PRIORIX Prescribing Information.
Brands mentioned are trademarks of their respective owners.
ATP, according-to-protocol; GMC, geometric mean concentration; SRR, seroresponse rate.

Actor Portrayal

References

  1. Centers for Disease Control and Prevention. Measles Vaccination. Updated January 17, 2025. Accessed October 22, 2025. https://www.cdc.gov/measles/vaccines/index.html
  2. PRIORIX. Prescribing Information. GSK; 2024.
  3. Abu-Elyazeed R, Jennings W, Severance R, Noss M, Caplanusi A, Povey M, Henry O. (2018). Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study. Hum Vaccin Immunother. 2018; 14(11), 2624–2631. https://doi.org/10.1080/21645515.2018.1489186

Indications and Usage

M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.

The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

Selected Safety Information

M-M-R®II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.

Due caution should be employed in administration of M-M-R®II to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.

Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual’s immune status has been evaluated and the individual has been found to be immunocompetent.

Immune globulins (IG) and other blood products should not be given concurrently with M-M-R®II. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.

The following adverse reactions have been identified during both the subcutaneous and intramuscular use of M-M-R®II or its components in clinical trials or reported during post-approval use: fever, rash, and injection-site reactions.

The following adverse reactions have been identified during the subcutaneous use of M-M-R®II or its components in clinical trials or reported during post-approval use: headache, dizziness, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.

Dosage and administration

FOR INTRAMUSCULAR OR SUBCUTANEOUS USE ONLY.

M-M-R®II vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R®II vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.

 

Before administering M-M-R®II, please read the accompanying Prescribing Information. The Patient Information also is available.

 

Indications and Usage
Selected Safety Information

M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.

The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

Selected Safety Information

M-M-R®II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.

Due caution should be employed in administration of M-M-R®II to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.

Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual’s immune status has been evaluated and the individual has been found to be immunocompetent.

Immune globulins (IG) and other blood products should not be given concurrently with M-M-R®II. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.

The following adverse reactions have been identified during both the subcutaneous and intramuscular use of M-M-R®II or its components in clinical trials or reported during post-approval use: fever, rash, and injection-site reactions.

The following adverse reactions have been identified during the subcutaneous use of M-M-R®II or its components in clinical trials or reported during post-approval use: headache, dizziness, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.

Dosage and administration

FOR INTRAMUSCULAR OR SUBCUTANEOUS USE ONLY.

M-M-R®II vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R®II vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.

 

Before administering M-M-R®II, please read the accompanying Prescribing Information. The Patient Information also is available.